

Analyst Name – Jeet B Bhayani

SEBI Registration No- INH000018142

Trade View Report-



Published Date	April 27th, 2026
Rating	BUY
Trade Type	Long Term
Stock Name	GLENMARK
Entry Price	2300
Target	2900
Stop Loss Price	2000
Target%	26%
SL%	13%

Rationale-

Glenmark Pharmaceuticals Limited (GPL) is currently undergoing a strategic transformation into an innovation-led organization, moving away from a pure generics focus. As of April 2026, the company has achieved a net-cash position and is scaling its global specialty brands.

Registered Address- 37, Joy Narayan Santra Lane, Howrah 711101
Principal Officer- Jeet B Bhayani
Email- jeetbhayani2017@gmail.com

1. Financial Rationale & Latest Performance (Q3 FY26)

The primary rationale for Glenmark's current valuation is its **improved balance sheet** and the **monetization of its innovation pipeline**.

- **Revenue Growth:** ₹3,901 Cr (Up **15.1%** YoY) for Q3 FY26.
- **EBITDA:** ₹870 Cr (Up **44.9%** YoY).
- **EBITDA Margin:** **22.4%** (expansion of over 400 bps YoY due to better product mix and cost discipline).
- **Net Profit (PAT):** ₹403 Cr (Up **15.9%** YoY).
- **Net Cash Position:** Ended Q3 with **~₹600 Cr net cash**, successfully transitioning from a debt-heavy company to a debt-free entity by March 2026.
- **Segment Strength:** India business (forming ~33% of revenue) grew **22%**, significantly outperforming the Indian Pharmaceutical Market (IPM) growth.

2. Key Growth Drivers

- **Innovation Pivot (Ryaltris):** Its flagship nasal spray, **Ryaltris**, is now a global brand with 50%+ growth. From **April 1, 2026**, Glenmark took direct control of its US commercialization (previously partnered with Hikma), which is expected to improve margins.
- **Respiratory & Dermatology Leadership:** Glenmark maintains a Top 3 rank in India for Respiratory and Dermatology. Recent launches like the **nebulized triple therapy** for COPD are seeing strong uptake.
- **GLP-1 Portfolio:** Launched **Lirafit (Liraglutide)** in India, positioning itself as a leader in the emerging biosimilar GLP-1 market for diabetes and obesity.
- **European Momentum:** Growth of 9% YoY, aided by the launch of **Winlevi** (acne treatment) in the UK and its recent approval across the European Union.
- **Regulatory Resolution:** The **Monroe (USA) facility** received a VAI status (Voluntary Action Indicated) in early 2026, allowing the company to restart commercial manufacturing and product launches from this site.

3. Upcoming Projects & Pipeline

- **US Launches (FY27):** Targeted launch of several complex injectables and respiratory products from the Monroe site over the next 12–18 months.
- **Oncology Assets:**
 - **QINHAYO™:** Advancing marketing authorizations in high-need markets.
 - **Trastuzumab Rezetecan:** Partnered ADC (Antibody-Drug Conjugate) targeting breast and gastric cancers.
- **Semaglutide (India):** Following the Liraglutide launch, the company recently introduced **GLIPIQ (Semaglutide)** in India (March 2026) to capture the oral anti-diabetic market.
- **China Market: Ryaltris** received approval in China with a commercial launch scheduled for **Q1 FY27**, representing a massive new patient base.

4. Key Risks to Monitor

- **Execution in the US:** Building an independent sales infrastructure for Ryaltris in the US involves high initial marketing costs and execution risk.
- **R&D Concentration:** Heavy reliance on a few innovative assets; any regulatory delay in clinical trials for the oncology pipeline could impact future growth projections.
- **Pricing Pressure:** Ongoing generic pricing erosion in the US market, although currently offset by specialty brand growth.

Building on the previous financial overview, here are the more granular "alpha" points that are currently driving Glenmark's (GPL) strategic value as of April 2026.

1. The "Ryaltris" Direct Commercialization Leap

- **Strategic Shift (Effective April 1, 2026):** Glenmark has officially taken over end-to-end commercialization of its blockbuster nasal spray, Ryaltris, in the U.S. market.
- **Margin Impact:** By moving away from its previous licensing partner (Hikma), Glenmark now captures the full value chain. This is expected to be a major contributor to the company sustaining its ~23% EBITDA margins.

- **Global Footprint:** The product is now launched in 55 countries (11 new markets added in FY26), including a recent critical approval in China.

2. Domination of the GLP-1 "Affordability" Market

- **GLIPIQ (Semaglutide) Launch:** In March 2026, Glenmark disrupted the Indian diabetes market by launching GLIPIQ (Semaglutide) at a price point of ₹325 per week.
- **First-Mover Advantage:** Following their earlier launch of Lirafit (Liraglutide), Glenmark is now the only Indian company with a comprehensive "Vial + Pen" injectable portfolio for GLP-1s, targeting a massive population of Type 2 Diabetics and obesity patients.
- **Patient Support:** They have launched the "Sankalp" program to assist with injection training, which management believes will drive superior patient retention compared to pure generic competitors.

3. The "Ichnos Glenmark Innovation" (IGI) Engine

- **Innovation Spin-off:** Its research arm, Ichnos Glenmark Innovation, is now a high-value biotech engine.
- **Key Asset (ISB 2001):** Their first-in-class trispecific antibody for Multiple Myeloma received FDA Fast Track Designation in early 2026.
- **Licensing Income:** A global licensing deal with AbbVie for ISB 2001 has already provided significant upfront payments, which helped Glenmark reach its Zero Gross Debt goal in March 2026.

4. Resolution of Regulatory Overhangs

- **Monroe Facility Turnaround:** The U.S. FDA recently upgraded the Monroe, North Carolina facility to VAI (Voluntary Action Indicated) status.
- **US Pipeline Unlock:** This allows Glenmark to restart manufacturing and finally launch its pending pipeline of complex injectables and sterile products, which had been stalled for years due to regulatory warnings.

5. Operational Efficiency & Cash Flow

- **Zero Debt Milestone:** As of March 31, 2026, Glenmark has successfully eliminated its gross debt, a transformation from being one of the more leveraged players in the sector just three years ago.
- **Capex Discipline:** The company has capped annual capex at ₹700–800 Crore, with 55% now allocated to intangible assets (R&D and in-licensing) rather than just brick-and-mortar factories.
- **Consumer Care Reach:** Their consumer business, led by Candid Powder, now holds over 56% market share, providing a high-margin, recession-proof cash flow stream.

Disclaimer-

Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Trading in Futures & Options (F&O) carries high risk as it depends on market momentum. "Registration granted by SEBI & Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to Investors." Past performance is no guarantee of future results.

Intraday- Not more than one day

Short term – 0-15 days

Medium term – 1- 3 months

Long term – more than a Year

DISCLOSURES WITH RESPECT TO RESEARCH AND RECOMMENDATIONS SERVICES

1. Research entity or Research Analyst or his associate or his relative may have financial interest or actual / beneficial ownership of one per cent or more in the securities recommended in its personal portfolio at the end of the month immediately preceding the date of publication of the research report or date of the public appearance. Details of the same may be referred through the disclosures made at the time of advice.
2. There are no actual or potential conflicts of interest arising from any connection of Research entity or Research Analyst or his associate or his relative to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of Research Analyst services. Such conflict of interest shall be disclosed to the client as and when they arise.
3. Research analyst or research entity or its associates or relatives, may have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance or research recommendation. Details of the same may be referred through the disclosures made at the time of advice.
4. Research entity or Research analyst or its associate or relatives has no connection or association of any sort with any issuer of products/ securities recommended herein.
5. Research analyst or his associate or his relative has no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of research and recommendations services.
6. Research entity or Research analyst or its associates has not received any kind of remuneration or consideration form the products/ securities recommended herein.
7. Research entity or Research analyst or its associates have not received any compensation from the subject company in past 12 months.
8. Research entity or Research analyst or its associates have not managed or co-managed the public offering of Subject Company in past 12 months.
9. Research entity or Research analyst or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company in past 12 months.
10. Research entity or Research analyst or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.
11. Research entity or Research analyst or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report or research recommendations.
12. Research entity or Research analyst or its associates have not received any compensation for products or services from the subject company in past 12 months.
13. The subject company is or was not a client of Research entity or Research analyst or its associates during twelve months preceding the date of distribution of the research report and recommendation services provided.
14. Research Analysts or its associates has not served as an officer, director or employee of the subject company.
15. Research Analysts has not been engaged in market making activity of the subject company.